Navigation Links
Waters CE Marks In Vitro Diagnostic MassTrak Immunosuppressants XE Kit
Date:7/25/2011

ATLANTA, July 25, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that its MassTrak™ Immunosuppressants XE Kit is now CE-marked in accordance with the IVD Directive 98/79/EC, for the quantitative measurement of the immunosuppressive drugs tacrolimus (FK506;Prograf®) in liver and kidney transplant patients and everolimus (Certican®) in adult kidney and cardiac transplant patients from human whole blood samples as an aid in the management of immunosuppressant drug therapy.

(Logo: http://photos.prnewswire.com/prnh/20110707/NE31586LOGO)

Waters LC/MS/MS system, consisting of the MassTrak™ Immunosuppressants XE Kit and method, the Waters ACQUITY UPLC® UltraPerformance Liquid Chromatography system coupled to an ACQUITY® TQD tandem quadrupole mass spectrometer, offers enhanced sensitivity and specificity, and measures target compounds at low ng/mL levels (0.5 ng/mL).

"LC/MS plays an increasingly important role in many clinical laboratories today. Waters is committed to advancing technology-based diagnostic solutions in the clinical laboratory that impact the quality of results in many  areas including immunosuppressant drug monitoring," said Mark Bruns, Senior Director, Clinical Business Operations, Waters Division.

With the instrumentation and kit, clinical laboratories in the European Economic Area and Switzerland will no longer have to spend time and money to develop and validate in house LC/MS/MS methods for tacrolimus or everolimus, or source calibrators, QCs, and internal standards. Waters clinical specialists will support the system and methodology.  

The instru
'/>"/>

SOURCE Waters Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Waters Introduces Ostro Sample Preparation Products
2. Waters Expands Xevo MS Instrument Platform With Next-Generation Mass Spectrometers
3. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
4. Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard
5. New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals
6. Aprima Earns High Marks at Holy Name Medical Center
7. DecisionView to Create Clinical Trial Enrollment Benchmarks
8. Carl Marks Advises Scovill Fasteners in Sale of Company
9. Oncology Global Strategic Marketing Study Offers Chance for Resource Benchmarks
10. Stretch Marks the Spot
11. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 ... Inc. (NASDAQ: REGN) today announced that the New ... Phase 2a study results of dupilumab (SAR231893/REGN668) in patients ... antibody targeting the alpha subunit of the interleukin 4 ... and IL-13, drivers of Th2 (Type 2 helper T ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... 10, 2011 Sanofi-aventis (EURONEXT: SAN and ... (Nasdaq: REGN ) today announced results from ... aflibercept (VEGF Trap) for the second-line treatment of non-small ... aflibercept to the chemotherapy drug docetaxel did not meet ...
... 2011 Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... December 31, 2010, and provided a business update. The ... $0.06 per share, compared with a net loss for 2009 of ... $20.0 million, compared with $22.0 million for 2009.  Gross profit was ...
Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7Transgenomic Reports Fourth Quarter Financial Results 2Transgenomic Reports Fourth Quarter Financial Results 3Transgenomic Reports Fourth Quarter Financial Results 4Transgenomic Reports Fourth Quarter Financial Results 5Transgenomic Reports Fourth Quarter Financial Results 6Transgenomic Reports Fourth Quarter Financial Results 7
(Date:5/21/2013)... 21, 2013 According to a May 13, ... Use of Botox,” Botox injections have become the ... in 2002 (Go to goo.gl/8iYbD). Although it is mostly associated ... men. The injection makes facial wrinkles less visible by paralyzing ... for about three months. This means that people who are ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to ... in the Creative Corridor region, is releasing results for ... conference on Thursday, May 23rd at 10:30 a.m. ... , The survey is a critical component ... that attract, nurture and retain people of diverse backgrounds, ...
(Date:5/21/2013)... (May 21, 2013) A paper recently published in ... co-written by physicians and scientists at the University of ... risk factor for pulmonary fibrosis can be used to ... , Researchers looked at a fairly common variant of ... component of the mucous produced by the bronchial tubes. ...
(Date:5/21/2013)... for scientific and technological research So Paulo Research Foundation, ... an investment estimated in US$ 680 million to support ... period of up to eleven years, subject to continuation ... Funding for the 17 RIDCs will come from FAPESP ... personnel, and infrastructure). Host institutions will participate in a ...
(Date:5/21/2013)... Park City, Utah (PRWEB) May 21, 2013 ... on HRA, HSA and FSA accounts. Zane ... employer sponsored health benefits, is the leader in ... health reimbursement arrangements . , According to Zane ... or health reform) was signed into law in 2010 ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3
... rates of hospital use, but they may be experiencing ... said in the latest edition of the Medical ... Melbourne-based Refugee Health Research Centre, Dr Ignacio Correa-Velez, and ... financial years to June 2004. ,'We found ...
... -- The science has long been clear that smoking causes ... damage from a father who smokes . ,Canadian ... in the DNA sequence of sperm cells, alterations that could ... are published in the June 1 issue of Cancer Research, ...
... market is estimated at around $2.5 trillion per annum, ... percent per annum. A radical shift in food consumption ... ,In markets, especially in the developed world, with ... is rapidly increasing. Besides, the emerging health-conscious newer generation ...
... released by a growing tumor could one day become ... chemotherapy and radiation treatment in people with advanced throat ... 1, 2007, issue of Clinical Cancer Research. ... Communication Disorders (NIDCD) and National Cancer Institute (NCI), two ...
... Researchers have found that patients with obstructive sleep apnea ... dead cells (apoptotic cells) from the lining (endothelium) of ... who do not have OSA. The finding may help ... for cardiovascular disease (CVD). ,According to the ...
... In a retrospective study of 700 patients with ... be significantly higher in HIV-infected patients compared ... TB relapse rates were higher in HIV-infected patients ... compared to those receiving daily or longer treatment. ...
Cached Medicine News:Health News:Cigarette Smoke Alters DNA in Sperm, Genetic Damage Could Pass to Offspring 2Health News:Nutrient-rich Dairy Beverages an Emerging Market 2Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 2Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 3Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 4Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 2Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 3Health News:Treatment Outcomes of Patients With HIV and Tuberculosis 2
Inquire...
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B2 Biological Safety Cabinet...
Class II Type A2 Biological Safety Cabinet...
Medicine Products: